Melbourne, Australia – 15 July 2024 | Heramed Ltd (ASX: HMD) ("Heramed" or the "Company"), a pioneering medical data and technology company transforming maternity care, is pleased to announce the signing of a five-year Strategic Partnership Agreement (SPA) with the University of Technology Sydney (UTS). This partnership is led by UTS's INSIGHT Health Research Institute, a renowned centre for innovative health solutions.
Key Highlights:
- Strategic Partnership: Heramed and UTS have entered a five-year strategic partnership through the leadership of INSIGHT Health Research Institute, focusing on improving the care and wellbeing of women and babies.
- Collaboration Scope: UTS, a leading Australian university with world-class research centres, will be Heramed’s strategic research partner in New South Wales, contributing to and building on existing research collaborations.
- INSIGHT's Role: INSIGHT is UTS’s Research Institute for Innovative Solutions for Well-being and Health, specializing in Women and Children's Health, and will work with Heramed to develop new models of care.
- Research Focus: The partnership aims to change the models of care for women and babies through knowledge generation, exchange, translation, and impact.
- Support for Strategic Plan: The UTS partnership supports Heramed's Four-Point Strategic Plan by advancing strategic partnerships and research grant opportunities.
The SPA with UTS is designed to foster cross-collaborative research efforts engaging multiple faculties, institutes, and centres within UTS. This collaboration will focus on delivering sustainable, scalable solutions to entrenched health problems, particularly in maternal and infant health.
Anoushka Gungadin, Managing Director & CEO of Heramed, stated: “HeraMED is excited to work in partnership with UTS to advance models of care and wellbeing for women and babies. Through this long-term strategic research program, we look forward to working collaboratively with UTS across all relevant faculties and disciplines as well as broader stakeholders, decision and policy makers including government, hospital and healthcare providers.”
Professor Susan Morton, Director of UTS INSIGHT, added: “Partnering with HeraMED provides an exciting opportunity to apply our research expertise to real-world challenges in maternal and infant health from a life course perspective. This research program is expected to support important research related knowledge generation, exchange, translation, and impact for the ultimate benefit of women, babies, and the broader community.”
Advancing Strategic Objectives:
The partnership with UTS significantly enhances Heramed’s access to a broader range of research grants. UTS’s established track record and academic credibility will enable Heramed to jointly pursue funding from prestigious bodies such as the Australian Research Council (ARC), the Medical Research Future Fund (MRFF), and the National Health and Medical Research Council (NHMRC).
By aligning projects with cutting-edge research priorities, Heramed aims to build evidence-based models of care, increasing potential for funding from government bodies, private foundations, and long-term funding streams. This strategic collaboration will support sustained research and development efforts to improve maternal and infant health outcomes.
HeraMED Limited
Managing Director & CEO
Anoushka Gungadin
M: +61 431 131 649
E: anoushka@hera-med.com
CFO & Company Secretary
Cameron Jones
T: +61 400 086 399
E: cameron.jones@bio101.com
Chairman
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au
Investor & Media Relations
Jane Morgan
M: +61 405 555 618
E: jm@janemorganmanagement.com.au
About us:
About HeraMED Limited (ASX:HMD)
HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.
The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.
About UTS INSIGHT
Launched in June 2023, INSIGHT is a unique pan-university Health Research Institute generating innovative solutions to entrenched health problems. It does this by working across traditional research boundaries to accelerate multidisciplinary collaboration that delivers sustainable well-being and health solutions at scale. Our projects are ambitious, multi-faculty and partnered, and take a person-centred, life course view of health and well-being with an explicit aim of reducing inequities in health outcomes.
Read more: https://www.uts.edu.au/about/faculty-health/faculty-health-research/insight
Contact details:
Jane Morgan
Jane Morgan Management
Investor Relations
jm@janemorganmanagement.com.au
